Prognostic relevance of anemia and transfusion dependency in myelodysplastic syndromes and primary myelofibrosis

Anemia is a cardinal manifestation of myelodysplastic syndromes (MDS) and primary myelofibrosis (PMF). Over half (54%) of the patients with de novo untreated myelodysplastic syndromes, in the International Prognostic Scoring System (IPSS) cohort, presented with hemoglobin levels of less than 10 g/dL.1 In another independent cohort with IPSS low or intermediate-1 risk myelodysplastic syndromes, an almost identical proportion (55%) of patients presented with a similar degree of anemia.2 Similarly, most patients with primary myelofibrosis are anemic at presentation and the hemoglobin level was less than 10 g/dL in 35% to 54% of patients in some studies.3,4

The pathogenesis of anemia in both myelodysplastic syndromes and primary myelofibrosis is poorly understood and is attributed to “ineffective erythropoiesis” for convenience. Because both disorders are markedly heterogeneous in their molecular and biological features, it is reasonable to assume that multiple factors contribute to the associated erythropoietic defect. In myelodysplastic syndromes, these include haploinsufficiency of genes and microRNAs in commonly deleted chromosomal regions, mitochondrial dysfunction, acquired abnormalities of hemoglobin synthesis, and abnormal expression of proinflammatory cytokines and other growth factors.5 The latter has also been implicated in PMF-associated ineffective hematopoiesis;6 additional contributing factors to MF-associated anemia include mutation profile (presence of JAK2V617F7 might be favorable and MPL8 and TET29 mutations unfavorable in this regard),10 bone marrow stromal changes, hypersplenism and chronic low grade hemolysis.11

Anemia has long been recognized as an adverse prognostic factor for overall survival in myelodysplastic syndromes.1,12,13 With the introduction of the World Health Organization (WHO) classification system there has been a re-examination of prognostic factors in myelodysplastic syndromes.14,15 In a study of 467 de novo MDS patients, the development of red blood cell transfusion need was associated with significantly shorter overall and leukemia-free survival in myelodysplastic syndromes without excess blasts.16 Subsequently, a dynamic prognostic model that takes red blood cell transfusion need into account was developed and further validated in an independent cohort of 739 de novo myelodysplastic syndrome patients.17 Similarly, red blood cell transfusion need was identified as a strong and independent risk factor for survival in ‘myelodysplastic syndrome with isolated del(5q)’18 and refractory anemia with ring sideroblasts (RARS).19 Anemia sustained its independent prognostic value even in low and intermediate-1 risk patients with myelodysplastic syndromes2 and red blood cell transfusion need was shown to be an IPSS-independent risk factor in a more recent practical prognostic model that included 1,915 patients with primary and secondary myelodysplastic syndromes and chronic myelomonocytic leukemia.20

Anemia is a powerful risk factor also in primary myelofibrosis. The International Prognostic Scoring System (IPSS) for PMF was recently developed to assess survival from the time of diagnosis.3 The IPSS-derived dynamic IPSS (DIPSS) is used to predict survival from any time point in the disease course.21 Both IPSS and DIPSS utilize hemoglobin less than 10 g/dL as one of five risk factors (the others being age >65 years, leukocyte count >25×10/L, circulating blasts ≥ 1% and constitutional symptoms) in order to classify patients into four risk groups: low, intermediate-1, intermediate-2 and high. Considering the stronger prognostic effect of anemia, the DIPSS prognostic model assigns two adverse points for hemoglobin less than 10 g/d whereas the other four risk factors are each assigned one adverse point.21

More recently, red blood cell transfusion need was identified as an IPSS22,23 and DIPSS23 independent risk factor in primary meylofibrosis. Accordingly, a new prognostic model (DIPSS-plus) has been established and includes red blood cell transfusion need as one of eight risk factors; the other seven were age over 65 years, hemoglobin less than 10 g/dL, leukocyte count greater than 25×10/L, circulating blasts 1% or over, constitutional symptoms, platelet count less than 100×10/L and unfavorable karyotype.4 The 8 DIPSS-plus risk factors were used to define low (no risk factors), intermediate-1 (one risk factor), intermediate-2 (two or three risk factors) and high (four or more risk factors) risk primary myelofibrosis with respective median survivals of 15.4, 6.5, 2.9 and 1.3 years.4 In the DIPSS-plus prognostic model, red blood cell transfusion need was not independently associated with inferior leukemia-free survival whereas earlier studies suggested such an association.4,24

We believe that the presence and severity of anemia in both myelodysplastic syndromes and primary myelofibrosis signify a clonally advanced and biologically more aggressive disease. This, in our opinion, is the primary reason for the negative prognostic impact of anemia in these diseases. Based on strictly retrospective data analysis and using surrogate markers of questionable value, some investigators have considered the possibility that iron overload contributes to the association between poor survival and red blood cell transfusion need in myelodysplastic syndromes. This unsubstantiated claim has further been propagated by additional and equally misinterpreted retrospective studies in the context of allogeneic stem cell transplantation. In a series of studies from the Mayo Clinic, iron overload, measured by both transfusion burden and serum ferritin level, did not carry an independent prognostic value in RARS,19 myelodysplastic syndromes associated with isolated del(5q)19 or primary myelofibrosis.25 Furthermore, the value of serum ferritin as a surrogate for iron overload is confounded by its nature as an acute phase reactant; it might influence survival for reasons that have nothing to do with iron overload. Therefore, it would be much more rewarding to focus interest and research on the mechanisms of impaired hematopoiesis and its effect on prognosis rather than continuing to rework the possibly non-existing role of iron overload in such matters. In this regard, we continue to be amazed by the power of Pharma to turn the attention of the MDS community from scientifically-relevant to industry-relevant issues.

Footnotes

• Animesh Pardanani is a Consultant in the Division of Hematology at Mayo Clinic. Ayalew Tefferi is a professor of medicine and hematology at the Mayo Clinic in Rochester, MN, USA.
• (Related Original Article on page 167)
• Financial and other disclosures provided by the author using the ICMJE (www.icmje.org) Uniform Format for Disclosure of Competing Interests are available with the full text of this paper at www.haematologica.org.